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Fyn null mice display reduced adiposity associated
with increased fatty acid oxidation, energy expendi-
ture, and activation of the AMP-dependent protein
kinase (AMPK) in skeletal muscle and adipose tissue.
The acute pharmacological inhibition of Fyn kinase
activity with SU6656 in wild-type mice reproduces
these metabolic effects and induced a specific
reduction in fat mass with no change in lean mass.
LKB1, the main upstream AMPK kinase (AMPKK)
in peripheral tissues, was redistributed from the
nucleus into the cytoplasm of cells treated with
SU6656 and in cells expressing a kinase-deficient,
but not a constitutively kinase-active, Fyn mutant.
Moreover, Fyn kinase directly phosphorylated LKB1
on tyrosine 261 and 365 residues, and mutations of
these sites resulted in LKB1 export into the cyto-
plasm and increased AMPK phosphorylation. These
data demonstrate a crosstalk between Fyn tyrosine
kinase and the AMPK energy-sensing pathway,
through Fyn-dependent regulation of the AMPK
upstream activator LKB1.
INTRODUCTION
Fyn is a member of the large Src family of nonreceptor tyro-
sine kinases that share conserved structural domains. The Src
homology 1 (SH1) domain contains the catalytic tyrosine kinase
activity, and the SH2 domain binds to tyrosine-phosphorylated
substrates. In particular, Fyn SH2 domain binds the tyrosine
528 residue in the carboxy-terminal tail of the protein, stabilizing
the structure into an inactive conformation, thereby inhibiting the
tyrosine kinase SH1 domain (Sicheri and Kuriyan, 1997; Sicheri
et al., 1997; Songyang et al., 1995). The dephosphorylation of
this site is required to release the SH2 domain and to activate
the tyrosine kinase activity of Fyn.
Several studies have implicated Src kinase family members
in mediating a subset of insulin signaling events. For example,
Fyn was reported to directly associates with insulin-stimulated
tyrosine-phosphorylated IRS and c-Cbl proteins (Myers et al.,
1996; Ribon et al., 1998; Sun et al., 1996). In addition, Src family
kinases have been found to activate the phosphatidylinositol (PI)Cell M3-kinase signaling pathway, an established link to the stimula-
tion of glucose transport in skeletal muscle and adipocytes
(Choudhury et al., 2006). Upon posttranslational modifications
such as palmitoylation and/or N-myristoylation, the Fyn kinase
dynamically and reversibly redistributes between the cell interior
and the plasma membrane (Alland et al., 1994; Filipp et al.,
2003; Shenoy-Scaria et al., 1994). Several studies have also
implicated Fyn in the regulation of insulin signaling through
lipid raft microdomains. For example, Fyn was reported to be
the kinase responsible for 3T3L1 adipocyte insulin-stimulated
caveolin tyrosine phosphorylation and to associate with lipid
raft proteins flotilin and CD36 (Bull et al., 1994; Huang et al.,
1991; Mastick and Saltiel, 1997). In this regard, CD36, also
known as fatty acid translocase (FAT), facilitates long-chain
fatty acid uptake in skeletal muscle and adipose tissue and is
linked to phenotypic features of the metabolic syndrome,
including insulin resistance and dyslipidemia (Drover and
Abumrad, 2005; Drover et al., 2005; Meex et al., 2005; Pravenec
et al., 2003). Thus, the physical association of Fyn with CD36
further suggests a functional coupling between lipid raft
organization and the regulation of fatty acid translocation and
potentially fatty acid metabolism. More recently, we found that
Fyn null mice display markedly improved insulin sensitivity and
improved plasma and tissue triglyceride/nonesterified fatty
acid levels coupled with higher rates of energy expenditure
and fatty acid oxidation in the fasted state (Bastie et al.,
2007). This was directly correlated with increased AMP-depen-
dent protein kinase (AMPK) T172 a subunit phosphorylation,
increased AMPK activity, and inhibition of acetyl-CoA carbox-
ylase (ACC) function.
AMPK is a heterotrimeric complex composed of one catalytic
a plus two regulatory subunits, b and g. Each functional AMPK
complex is composed of multiple isoforms with overlapping
tissue distributions (Cheung et al., 2000; Daval et al., 2006). Skel-
etal muscle primarily expresses the a2 subunit as well as both
b and all three g isoforms, whereas adipose tissue primarily
expresses the a1 subunit with both b and g1 and g2 isoforms
(Daval et al., 2006; Towler and Hardie, 2007). The regulation of
AMPK activity depends on the type of subunits assembled and
cellular energy status, being activated when the AMP/ATP ratio
increases, which occurs in states of cellular nutritional defi-
ciency. Binding of AMP to the g subunit results in a conforma-
tional change that may decrease AMPK as a substrate for the
PP2C phosphatase (Steinberg, 2007). Alternatively, it was
reported that AMP binding increases the ability of upstream
kinases (AMPK kinases) to phosphorylate the activatingetabolism 11, 113–124, February 3, 2010 ª2010 Elsevier Inc. 113
Cell Metabolism
Fyn Regulation of Energy Expenditurethreonine residue (T172) in the a subunit (Towler and Hardie,
2007). In neurons, the calcium-stimulated activation of AMPK
is dependent upon the Ca2+/calmodulin-dependent protein
kinase kinase (CaMKK) family that phosphorylates the a subunit
T172 residue (Hawley et al., 2005). Although CaMKKs have also
been shown to activate AMPK in the skeletal muscle under mild
tetanic contraction, CAMKK expression is very low in peripheral
tissues and is primarily restricted to brain, testis, thymus, and
T cells (Jensen et al., 2007; Anderson et al., 1998). In contrast,
LKB1 is expressed in insulin-responsive tissues, and muscle-
specific LKB1 knockout mice are unable to activate AMPK
(Alessi et al., 2006; Sakamoto et al., 2005).
LKB1 is a serine/threonine kinase originally identified as a
tumor suppressor protein mutated in Peutz-Jeghers syndrome
that controls diverse cellular processes, including cellular polar-
ity, cancer, and metabolism (Hemminki et al., 1997; Jenne et al.,
1998). Regulation of LKB1 appears to be a complex process that
involves phosphorylation on diverse residues (S31, S325, T366,
and S431) and association into a ternary complex with MO25
and STRADa or STRADb. Serine 431 in LKB1 is highly conserved
in all organisms exceptCaenorhabditis elegans and is phosphor-
ylated by p90 ribosomal S6 protein kinase (RSK) and protein
kinase A (PKA). Although the phosphorylation of S431 was
initially described as critical for LKB1 activity, more recent
studies have suggested that it might not be necessary and that
other activation mechanisms might exist (Fogarty and Hardie,
2009). In particular, LKB1 subcellular localization is an important
event regulating LKB1 activity, as LKB1 functions as a tumor
suppressor only when it localizes in the cytoplasm and appears
to be inactive when restricted to the nucleus of cells (Alessi et al.,
2006). Recent studies have demonstrated that MO25 stabilizes
the interactions between LKB1 and STRADa and that the ternary
complex is cytoplasmically localized, whereas the monomeric
LKB1 protein and/or the dimeric LKB1/MO25 complex are
primarily nuclear localized (Boudeau et al., 2003). In addition,
LKB1 was reported to undergo sirtuin-mediated deacetylation
with the acetylated form restricted to the nucleus and was redis-
tributed to the cytoplasm following deacetylation (Lan et al.,
2008).
We recently reported that conventional Fyn knockout mice
displayed increased energy expenditure and fatty acid oxida-
tion due to increased activation of adipose tissue and skeletal
muscle AMPK activity, resulting in reduced adipose tissue
mass and enhanced insulin sensitivity (Bastie et al., 2007).
Importantly, the enhanced catabolism occurred predominantly
in the fasted state, and the Fyn null mice were able to convert
to a normal anabolic state during the feeding cycle. These data
suggested that pharmacological inhibition of Fyn function
could induce selective weight loss by decreasing fat mass
and simultaneously increasing insulin sensitivity. In addition,
this approach would identify the acute role of the Fyn tyrosine
kinase activity in adult animals without regard to putative
developmental/adaptive changes present in the conventional
Fyn null mice. In this study, we examined the physiologic
and molecular signaling events regulating energy metabolism
using the selective Src family kinase inhibitor SU6656 (Blake
et al., 2000). We observed that acute treatment with SU6656
rapidly increases energy expenditure, fatty acid oxidation,
and AMPK a subunit T172 phosphorylation in wild-type mice,114 Cell Metabolism 11, 113–124, February 3, 2010 ª2010 Elsevier Inmimicking the metabolic phenotype of the Fyn null mice. Mech-
anistically, AMPK activation resulted from a Fyn-dependent
tyrosine phosphorylation of LKB1 that regulates the subcellular
localization of LKB1 and activation of AMPK independent of
STRADa association. Together, these data describe a signaling
pathway accounting for the control of energy expenditure by
Fyn, and support the therapeutic potential of acute Fyn inhibi-
tion in vivo.
RESULTS
Fyn Activity Inhibition Increases Energy Expenditure
and Lipid Utilization
Loss of Fyn kinase protein in the conventional Fyn knockoutmice
leads to increased lipid utilization and energy expenditure,
particularly in the fasting/resting state (Bastie et al., 2007).
To examine the effects of acute Fyn inhibition, we investigated
the in vivo effects of the pharmacological selective Src family
kinase inhibitor SU6656. Wild-type mice were placed into meta-
bolic chambers and allowed to acclimatize for 48 hr. Intraperito-
neal injection of SU6656 or vehicle was performed at the begin-
ning of the light cycle (fasting/resting state), and the respiratory
quotient (RQ), oxygen consumption (VO2), energy expenditure
(EE), and physical activity were monitored for the following
12 hr. Both animal groups displayed identical carbohydrate utili-
zation during the dark cycle preceding the injection, as shown by
similarly high respiratory quotients (Figure 1A). As expected, the
RQ gradually decreased in the vehicle-treated mice during the
light cycle as themice normally switched to lipid utilization. How-
ever, the decrease of RQ was more pronounced in SU6656-
treated mice and was particularly more effective during the first
3 hr following the injection (Figure 1A). Oxygen consumption
and energy expenditure were similar in both groups before the
injection and were decreased during the light period as the
animals were resting with reduced basal metabolism. However,
both oxygen consumption and energy expenditure remained
14% more elevated in the SU6656-injected group (Figures 1B
and 1C) without any alteration in physical activity in either the
dark or light cycle (Figure 1D).
To examine whether the increased energy expenditure
resulted in weight loss in the SU6656-injected mice, total body
mass was evaluated before (T = 0 hr) and after (T = 12 hr) vehicle
and SU6656 injections (Figure 2A, left and right panels, respec-
tively). As mice generally consume 80% of their calories during
the dark cycle and have a limited food intake during the light
cycle, they undergo a diurnal pattern of weight gain and loss
as shown by the decreased body mass at T = 12 hr in the
vehicle-treated mice. The SU6656-treated animals also dis-
played decreased body weight 12 hr after the injection (Fig-
ure 2A, right panel), and the total weight loss was 40% greater
than that of the vehicle-treated group (Figure 2B). Lean mass
was slightly reduced during the light cycle, but there was no
significant difference between vehicle and SU6656-injected
mice (Figure 2C). In contrast, fat mass was significantly reduced
in the SU6656-treated mice compared to vehicle-injected
control animals (Figure 2D). To determine whether the lowered
RQ in the mice treated with SU6656 was directly due to
increased skeletal muscle fatty acid oxidation, red soleus and
white gastrocnemius muscles were isolated 3 hr following thec.
Figure 1. Acute Pharmacological Inhibition
of Fyn Increases Energy Expenditure
C57BL6/J males received an injection of vehicle
or SU6656 (4 mg/kg) at 0700 hr and were placed
into metabolic chambers without access to food.
Respiratory quotient (RQ) and oxygen consump-
tion (VO2) were recorded during the dark period
preceding the injection and during the light period
following the injection.
(A) Shown is respiratory quotient (RQ) from the
average of four mice injected with vehicle (open
circles) and four mice injected with SU6656 (dark
circles).
(B) Shown is VO2 recorded before (dark period)
and after the injection (light period).
(C) Energy expenditure (EE) was calculated using
the equation of Weir, EE (Kcal/kg/hr) = (3.815 3
VO2) + (1.232 3 VO2).
(D) Physical activity was recorded during the dark
(before injection) and light (after injection) periods;
0.001 < p < 0.01.
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The oxidation of 14C-palmitate to 14CO2 was increased 25%
and 33%, respectively, in the soleus and the gastrocnemius of
the SU6656-treated mice relative to vehicle treated controls
(Figures 3A and 3B). The SU6656-stimulated increase in fatty
acid oxidation occurred concomitantly, with an approximate
3-fold increased AMPK a subunit T172 phosphorylation and
increased ACC S79 (ACC1) and S221 (ACC2) phosphorylation
levels (Figures 3C and 3D).
Although SU6656 is a highly selective Src family kinase inhib-
itor, it is not specific for Fyn. Thus, these data do not exclude
a role for other Src family kinases in mediating these metabolic
effects. To address this issue, we examined the metabolic effect
of SU6656 onwild-type versus Fyn knockout mice. As previously
reported (Bastie et al., 2007), Fyn null mice display a marked
reduction in RQ compared to wild-type mice (Figure 3E). Simi-
larly to Figure 1, SU6656 treatment of wild-type mice resulted
in an enhanced conversion to fatty acid utilization characterized
by a lower RQ (Figure 3E, filled versus open circles). In contrast,
SU6656 treatment had no significant effect on the rate of change
or the RQ level in the Fyn knockout mice (Figure 3E, filled versus
open diamonds). In addition, we did not observe any alterations
of body mass or physical activity after SU6656 treatment in the
Fyn null mice (see Figure S1 available online). As the two most
closely related kinases to Fyn are Src and Lyn, we examined
the protein expression levels of Src and Lyn proteins in the Fyn
null mice. As shown in Figure 3F, the levels of Src were
unchanged in adipose tissue, liver, or skeletal muscle of the
Fyn null mice. Although Lyn is not expressed in skeletal muscle,Cell Metabolism 11, 113–124there was no change in expression in
either adipose tissue or liver. Thus, the
lack of effect of SU6656 was not due to
altered expression of Src or Lyn expres-
sion in the Fyn null mice. Taken together,
these results demonstrate that an acute
treatment with SU6656 increases whole-
body energy expenditure and skeletal
muscle fatty acid oxidation, decreasesadiposity, and promotes weight loss most likely through a Fyn
kinase-dependent mechanism.
Fyn Regulates LKB1 Subcellular Localization
Previous studies have demonstrated that LKB1 is predominantly
nuclear localized in cultured cells, whereas its substrate target,
AMPK, is primarily localized to the cytoplasm (Alessi et al.,
2006). To determine if Fyn regulates LKB1 localization, we trans-
fected the C2C12 muscle cell line with GFP-LKB1 and examined
the effect of acute SU6656 treatment on subcellular LKB1 local-
ization (Figure 4). As previously reported (Nezu et al., 1999; Tiai-
nen et al., 2002), in vehicle-treated cells the majority of the LKB1
was nuclear localized (Figures 4A and 4B). However, treatment
with SU6656 resulted in the redistribution of LKB1 into the cyto-
plasm in approximately 65% of the cells. Figure S2 shows repre-
sentative images of multiple C2C12 cells treated with Vehicle
(Figure S2A) or SU6656 (Figure S2B). Since the concentration
of SU6656 (10 mM) is sufficient to inactivate Fyn kinase activity
(Blake et al., 2000), this suggests that LKB1 subcellular localiza-
tion was controlled by the catalytic activity of Fyn. We therefore
transfected C2C12 and 3T3L1 adipocytes with a constitutively
active Fynmutant (Fyn-CA) in which the negative regulatory tyro-
sine (Y528) site was mutated to phenylalanine and a kinase-
defective mutant (Fyn-KD) in which the catalytic lysine (K299)
residue was mutated to methionine. Expression of Fyn-CA in
C2C12 appeared to alter the morphology to a more rounded
phenotype, but there was no significant effect on the nuclear
localization of LKB1, whereas expression of Fyn-KD had no
morphology effect but resulted in a redistribution of more than, February 3, 2010 ª2010 Elsevier Inc. 115
Figure 2. SU6656-Induced Fyn Inhibition
Promotes Fat Mass Loss
(A) Body weight distribution of vehicle and
SU6656-injected mice before (T = 0) and after
(T = 12 hr) the injection.
(B) Total weight loss 12 hr after the injection of
vehicle (open bar) and SU6656 (dark bar) treated
animals.
(C) Fat mass before (T = 0) and after (T = 12 hr)
vehicle or SU6656 injection.
(D) Lean mass before (T = 0) and after (T = 12 hr)
vehicle or SU6656 injection (see also Figure S1).
Results are expressed as mean ± SEM.
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(Figures 4C and 4D). Figure S3 shows representative images of
multiple C2C12 cells transfected with constitutively active
Fyn (Fyn-CA, Figure S3A) or kinase-defective Fyn (Fyn-KD,
Figure S3B).
In contrast to C2C12 cells, subcellular localization is more
readily visualized in adipocytes due to the presence of large lipid
droplets. Expression of Fyn-CA or Fyn-KD has no significant
effect on the morphology of the adipocytes (Figure 4E). LKB1
remained nuclear localized in the presence of Fyn-CA, whereas
expression of Fyn-KD resulted in decreased nuclear LKB1 with
an increased cytosolic localization (Figures 4E and 4F). Figure S4
shows representative images of multiple 3T3L1 adipocytes
transfected with constitutive active Fyn (Fyn-CA, Figure S4A)
or kinase-defective Fyn (Fyn-KD, Figure S4B).
Since STRADa has been reported to regulate intracellular
LKB1 distribution (Boudeau et al., 2003, 2004), we cotransfected
3T3L1 adipocytes with STRADa and either Fyn-CA or Fyn-KD
and examined subcellular localization of tagged LKB1. As previ-
ously observed, tagged LKB1 alone was localized to nuclei of
adipocytes (Figures S5Aa–S5c), but following coexpression
with STRADa, there was an efficient redistribution of LKB1 into
the cytoplasm (Figures S5Ad–S5Ag). However, LKB1 remained
nuclear localized when coexpressed with the constitutively
active form of Fyn kinase, even in the presence of STRADa (Fig-
ures S5Ba–S5Be). As a control, the expression of the kinase-
deficient Fyn (Fyn-KD) with STRADa had no additional effect116 Cell Metabolism 11, 113–124, February 3, 2010 ª2010 Elsevier Inc.on the cytoplasmic localization of LKB1
(Figures S2Bf–S2Bj). The quantification
of these data is presented in Figure S5C.
Due to the high expression levels of
endogenous MO25 in adipocytes, iden-
tical results were also obtained when
STRADa and MO25 were coexpressed
with LKB1 (data not shown).
LKB1 Is a Substrate for Fyn
Tyrosine Kinase
Since Fyn-KD, but not Fyn-CA, induced
the redistribution of LKB1 into the cyto-
plasm, we next examined whether LKB1
can interact and/or is a substrate for the
Fyn tyrosine kinase catalytic activity.
First, we observed that endogenousLKB1 coimmunoprecipitated with Fyn kinase in skeletal muscle
and in 3T3L1 adipocytes (Figures 5A and 5B). We next coex-
pressed Fyn with LKB1 in 3T3L1 adipocytes. Immunoblotting
of LKB1 immunoprecipitates with the PY100 phosphotyrosine
antibody demonstrated Fyn-induced tyrosine phosphorylation
of LKB1 (Figures 5C and 5D). LKB1 is a direct substrate target
of Fyn, as purified His-LKB1-tagged fusion protein was tyrosine
phosphorylated by purified recombinant Fyn kinase in vitro
(Figure 5E). To identify the LKB1 tyrosine sites’ phosphorylated
by Fyn, we utilized Phosphosite Detector from JPT peptide
technology. As shown in Figure S6, 141 overlapping peptides
(12–15 residues in length) corresponding to the LKB1 sequence
were subjected to in vitro phosphorylation utilizing purified
recombinant Fyn tyrosine kinase. This analysis identified five
tyrosines (Y60, Y156, Y166, Y261, and Y365) as potential LKB1
phosphorylation acceptor sites for the Fyn kinase. To identify
the phosphorylation sites in vivo, we next generated single point
mutants where each tyrosine site was substituted by a phenylal-
anine residue. Coexpression of Fyn-CA with wild-type LKB1 and
each individual mutant demonstrated equal protein expression
levels for all LKB1 mutants (Figure 5F). Tyrosine phosphorylation
levels were decreased with LKB1-Y261F mutant, and a substan-
tially greater reduction was obtained with LKB1-Y365F (Fig-
ure 5G). In addition, while both single mutants (Y261F and
Y365F) partially reduced LKB1 phosphorylation, the double
mutation Y261/365F had a more pronounced decrease in
LKB1 tyrosine phosphorylation (Figures 5H and 5I).
Figure 3. Fyn-Specific Inhibition Increased
Skeletal Muscle Fatty Acid Oxidation and
T172 AMPK Phosphorylation
(A and B) Palmitate oxidation was determined in
(A) red muscle (soleus) and (B) white gastrocne-
mius muscle (White Gastroc.) of mice injected
with vehicle or SU6656 (4 mg/kg). Data are the
mean ± SE of five independent experiments.
(C) Shown are phospho-T(172)-AMPK and total
AMPK protein expression levels in white gastroc-
nemius of vehicle or SU6656-treated mice.
(D) Shown are phospho-ACC and total ACC
protein expression levels in white gastrocnemius
of vehicle or SU6656-treated mice.
(E) Three-month-old Fyn knockout (diamonds)
mice and their controls (circles) were treated with
vehicle (open symbols) or SU6656 (filled symbols)
at the beginning of the light cycle. Respiratory
quotient (RQ) was recorded during the preceding
dark period and during the 12 hr following the
injection.
(F) Shown are expression levels of Src and Lyn
kinase in white adipose tissue (WAT), liver,
gastrocnemius (Gastroc), and soleus muscle of
Fyn null mice (FynKO) and their controls (WT).
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Phosphorylation
Since inhibition of Fyn kinase activity by SU6656 treatment or
expression of a Fyn kinase-deficient mutant (dominant negative)
resulted in redistribution of LKB1 out of the nucleus, we exam-
ined the subcellular localization of the phosphorylation-defective
mutants of LKB1 (Figure 6). As previously observed, in adipo-
cytes wild-type LKB1 was predominantly nuclear localized as
well as the LKB1-Y60F mutant (Figures 6Aa–6Af). Similarly,
both LKB1 mutants Y156F and Y166F were also nuclear local-
ized (data not shown). In contrast, both the LKB1 Y261F and
Y365F mutants displayed a greater cytosolic distribution, similar
to that observed for the SU6656-treated and Fyn-KD-trans-
fected cells (Figures 6Ba–6Bf). Similarly, the LKB1 double muta-
tion Y261/365F displayed a predominant cytoplasmic distribu-
tion (Figures 6Ca–6Cc). To determine if the Fyn-dependent
tyrosine phosphorylation at Y261 and Y365 was directly respon-
sible for LKB1 nuclear localization, we coexpressed constitu-
tively active Fyn (Fyn-CA) with the LKB1-Y261/365F double
mutant. In this case, LKB1-Y261/365F remained cytosolic, andCell Metabolism 11, 113–124Fyn-CA was ineffective in redistributing
this mutant into the nucleus (Figures
6Da–6Dd). Quantification of these data
is presented in Figure 6E with approxi-
mately 20% of LKB1-WT and LKB1-
Y60F displaying a cytoplasmic localiza-
tion, whereas 55%–60% of LKB1-Y261F
and LKB1-Y365F were in the cytoplasm.
Moreover, nearly 90% of the LKB1-
Y261/365F double mutant was found
in the cytoplasm, and coexpression of
Fyn-CA was ineffective in altering the
subcellular localization of the LKB1-
Y261/365F double mutant.To confirm these results in vivo, we took advantage of skeletal
muscle transfection by electroporation as described previously
(Prud’homme et al., 2006). The expressed Flag-LKB1-WT is
predominantly detected in the muscle syncytia that parallel the
sarcolemma (Figures 7Aa–7Ac). In contrast, expression of the
Flag-LKB1-Y261/365F double mutant resulted in a more cyto-
plasmic localization (Figures 7Ad–7Af). The low level of nonspe-
cific background labeling is shown in Figures 7Ag–7Ai, and
a larger magnification of LKB1 localization is provided in Fig-
ure 7B. Although it is very difficult to detect the endogenous
LKB1 in vivo by immunofluorescence due to the quality of the
currently available antibodies, we also observed an increased
LKB1 signal in the cytoplasm of muscle cells of wild-type mice
treated with SU6656 (data not shown).
To determine if Fyn kinase also induces the tyrosine phosphor-
ylation of LKB1 in vivo, tibialis anterior muscles were transfected
with Fyn-CA, and endogenous LKB1 was immunoprecipitated
and immunoblotted with PY100 (Figure S7A and S7B). In the
absence of Fyn-CA, there was a relatively low level of LKB1 tyro-
sine phosphorylation that was significantly increased by the, February 3, 2010 ª2010 Elsevier Inc. 117
Figure 4. Fyn Kinase Activity Regulates
LKB1 Subcellular Distribution
(A) C2C12 myotubes were transfected with
pEGFP-LKB1 and incubated with vehicle or
SU6656 (10 mM) for 2 hr. Cells were fixed and
mounted with proQ diamond with DAPI solution.
(B) Shown is percentage of cells with pEGFP-
LKB1 signal detected in the cytoplasm.
(C) C2C12 myotubes were cotransfected with
pEGFP-LKB1 and pcDNA3-Fyn-KD or pcDNA3-
Fyn-CA. Cells were fixed and incubated with the
mouse Fyn monoclonal antibody. Immunofluores-
cence was performed using the Alexa Fluor 594
Anti-mouse IgG.
(D) Percentage of C2C12 cells with pEGFP-LKB1
signal detected in the cytoplasm. Data are repre-
sentative of n = 5 experiments.
(E) Fully differentiated 3T3L1 adipocytes were
cotransfected with pcDNA3-LKB1 and pcDNA3-
Fyn-KD or pcDNA3-Fyn-CA. Immunofluorescence
was performed using the rabbit LKB1 polyclonal
antibody and mouse Fyn monoclonal antibody
followed by Alexa Fluor 488 anti-rabbit IgG and
Alexa Fluor 564 anti-mouse IgG.
(F) Percentage of 3T3L1 cells with LKB1 signal
detected in the cytoplasm. Data are representative
of n = 5 experiments (see also Figures S2–S5).
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quence of LKB1 distribution, we first assessed the effect of the
LKB1-Y261/365F double mutant on AMPK phosphorylation by
coexpression with the GST-AMPK a subunit in HeLa cells. There
was a low level of AMPK a subunit T172 phosphorylation when
coexpressed with LKB1-WT that was increased in the presence
of the LKB1-Y261/365F double mutant (Figure S7C). Moreover,
there was a marked increase in endogenous AMPK a subunit
T172 phosphorylation in tibialis anterior muscle transfected
with the LKB1-Y261/365F double mutant compared to LKB1-
WT (Figure S7D).
DISCUSSION
AMP-activated protein kinase (AMPK) is considered a cellular
‘‘energy sensor’’ directly regulated by alterations of the intracel-
lular AMP/ATP ratio that occur during prolonged fasting and
refeeding (Hardie, 2008a; Hardie et al., 2006; Hue and Rider,
2007; Schimmack et al., 2006). During states of low energy, acti-
vation of AMPK results in the phosphorylation and inhibition
of ACC activity, thereby lowering malonyl-CoA levels, leading
to increased fatty acid oxidation and a reduction in fatty acid118 Cell Metabolism 11, 113–124, February 3, 2010 ª2010 Elsevier Inc.synthesis (Brownsey et al., 2006). In
contrast, during states of caloric excess
AMPK is inactive, resulting in increased
ACC activity and inhibition of fatty acid
oxidation with a concomitant increase in
fatty acid storage. The critical role of
AMPK in determining energy balance
has been clearly demonstrated in both
AMPK knockout and overexpression of
dominant-interfering AMPK mutants thatdisplay insulin resistance, reduced energy expenditure, and
inability to undergo normal metabolic switching between carbo-
hydrate and fatty acid fuels (Hardie, 2008a, 2008b; Viollet et al.,
2003). Thus, mechanisms and factors controlling AMPK activity
are key issues in the balance of lipid and glucose metabolism
that may provide novel therapeutic opportunities.
Previously, we demonstrated that Fyn functions as a negative
regulator of fatty acid oxidation through the inhibition of AMPK in
skeletal muscle and adipose tissue (Bastie et al., 2007). This was
based upon the observation that conventional Fyn null mice dis-
played enhanced fatty acid oxidation in adipose tissue and skel-
etal muscle, increased AMPK activity, increased energy expen-
diture, and insulin sensitivity. However, due to the constitutive
loss of Fyn expression, these data could neither address poten-
tial developmental tissue adaptations that could be responsible
for these metabolic alterations nor distinguish whether this
resulted from a loss of Fyn kinase activity or protein interaction
functions. Therefore, the mechanism responsible for AMPK acti-
vation in the Fyn null mice remained enigmatic.
To address these issues, we first took advantage of a selective
pharmacological approach to acutely inhibit Src family kinase
activity that recapitulated the metabolic phenotype observed in
Figure 5. Fyn Phosphorylates LKB1 on
Tyrosine Residues 261 and 365
(A and B) (A) Gastrocnemius muscle and (B) differ-
entiated 3T3L1 adipocyte extracts were immuno-
precipitated with IgG or the Fyn rabbit polyclonal
antibody and immunoblotted with the monoclonal
LKB1 antibody. 3T3L1 adipocytes were trans-
fected with the pcDNA3 empty vector or
pcDNA3-Fyn construct.
(C) Cell extracts (lysates) were immunoblotted for
Fyn and LKB1.
(D) Cell extracts were immunoprecipitated with the
LKB1 monoclonal antibody and immunoblotted
with the phosphotyrosine antibody (PY100) or
LKB1 antibody.
(E) Purified His-tagged LKB1 was incubated with
ATP in the absence and presence of purified Fyn
protein. The samples were then immunoblotted
with the LKB1 antibody and the phosphotyrosine
antibody PY100.
(F) pcDNA3-Flag-LKB1 mutant cDNAs and the
pcDNA3-Fyn-CA constructs were coexpressed
in 3T3L1 adipocytes, and levels of expression
were determined in whole-cell extracts.
(G) Levels of tyrosine phosphorylation of each
LKB1 construct were determined in Flag immuno-
precipitates subjected to immunoblotting with
PY100. pcDNA3-Flag-LKB1-Y261/365F double
mutant and pcDNA3-Fyn-CA constructs were
coexpressed in 3T3L1 adipocytes.
(H) The levels of LKB1 expression were deter-
mined by immunobloting cell extracts with the
Flag and Fyn antibodies, respectively.
(I) LKB1 tyrosine phosphorylation was determined
by LKB1 immunoprecipitation followed by immu-
noblotting with the PY100 and Flag antibodies
(see also Figure S6).
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energy expenditure, and AMPK active site phosphorylation.
The metabolic effect of the SU6656 inhibitor was likely specific
for Fyn, as this agent had no effect in Fyn null mice. These
changes in whole-body metabolism occurred relatively rapidly
(2–3 hr) upon acute treatment with SU6656, consistent with inhi-
bition of Fyn kinase activity rather than developmental compen-
sation or other Fyn-protein interactions being responsible for
the observed phenotype. Moreover, the phenotypic characteris-
tics of Fyn inhibition are essentially the same as those reported
for other animal models with increased AMPK activity (Viollet
et al., 2009). Taken together, these data strongly indicate that
Fyn kinase activity per se serves to functionally inhibit AMPK
activity. Importantly, the acute inhibition of Fyn resulted in signif-
icant weight loss due to decreased adipose tissue mass without
any significant change in lean mass, supporting a potential ther-
apeutic approach for modulating Fyn function.
In this regard, the primary upstream kinase activator of AMPK
in peripheral tissues is LKB1, and we speculated that this was
a potential Fyn target responsible for the regulation of AMPK.
Several studies have demonstrated that LKB1 activity depends
on its subcellular localization, LKB1 being active in the cyto-
plasm and inactive when restricted to the nucleus of culturedCell Mcells (Alessi et al., 2006; Baas et al., 2003). Since AMPK is
predominantly localized in the cytoplasm, nuclear export of
LKB1 would be required for LKB1-dependent phosphorylation
of AMPK. Our data demonstrate that activated Fyn kinase
activity maintains LKB1 predominantly in the nucleus and that
inhibition of Fyn kinase activity results in LKB1 redistribution
into the cytoplasm of cultured cells. Moreover, skeletal muscle
nuclei are peripherally organized adjacent to the sarcolemma,
and LKB1 is also peripherally localized in skeletal muscle
in vivo. Although there appears to be partial overlap with nuclei,
inhibition of Fyn kinase activity also results in LKB1 redistribution
into the cytoplasm in a manner similar to the cultured cells.
Mechanistically, our data indicate that Fyn-dependent regula-
tion of LKB1 localization occurs through the tyrosine phosphor-
ylation of two critical sites on LKB1 (Y261 and Y365). Mutational
analyses demonstrated that the loss of these phosphorylation
sites resulted in LKB1 cytoplasmic distribution and prevented
constitutively active Fyn from inducing LKB1 nuclear import.
The tyrosine phosphorylation regulation of LKB1 localization
was dominant over MO25/STRADa, as in the presence of
STRADa Fyn-CA was still able to drive nuclear import of LKB1.
Functionally, treatment with SU6656 or expression of the
LKB1-Y261/365F mutant that results in LKB1 cytoplasmicetabolism 11, 113–124, February 3, 2010 ª2010 Elsevier Inc. 119
Figure 6. LKB1 Tyrosine Phosphorylation
Regulates Its Subcellular Distribution
(A) 3T3L1 adipocytes were transfected with
pcDNA-Flag-LKB1-WT or the pcDNA-Flag-LKB1-
Y60F mutant cDNAs.
(B) 3T3L1 adipocytes were transfected with
the pcDNA-Flag-LKB1-Y261F and pcDNA-Flag-
LKB1-Y365F cDNAs.
(C) 3T3L1 adipocytes were transfected with
pcDNA-Flag-LKB1-Y261/365F double mutant
cDNA. Cells were fixed and subjected to immuno-
fluorescence for the localization of LKB1 (Flag
antibody) and DAPI labeling for nuclei identifica-
tion.
(D) 3T3L1 adipocytes were transfected with
pcDNA-Fyn-CA and the pcDNA-Flag-LKB1-
Y261/365F double mutant cDNAs. Cells were
fixed and subjected to immunofluorescence for
Fyn-CA expression (red), LKB1-Y261/365F double
mutant localization (green), and nuclei (blue).
(E) Percentage of 3T3L1 cells with LKB1 signal
detected in the cytoplasm. Data are representative
of n = 3 experiments.
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T172 both in skeletal muscle in vivo and in cultured cells.
We therefore propose a working hypothesis in which, similar
to other regulated proteins that undergo nuclear import/export
(i.e., Foxo1), LKB1 continually undergoes nuclear import/export
such that, under basal steady-state levels, the equilibrium
favors nuclear localization. However, this equilibrium shifts to
greater cytoplasmic localization by either increasing nuclear
export and/or reducing nuclear import through various regula-
tory events. For example, previous studies have shown that
these include binding to STRADa/MO25 and LKB1 deacetylation
(Boudeau et al., 2003; Lan et al., 2008). Since Fyn is predomi-
nantly a nonnuclear protein being distributed throughout the
cell including the plasma membrane, endomembranes, and the
cytoplasm (Alland et al., 1994; Davy et al., 1999; Filipp and Julius,
2004; Filipp et al., 2003; Parravicini et al., 2002), we hypothesize
that Fyn interacts with and tyrosine phosphorylates the nuclear
exported LKB1 that, in turn, increases its rate of nuclear import,
resulting in a high steady-state level of nuclear LKB1. Inhibition of
Fyn kinase prevents LKB1 tyrosine phosphorylation on Y261 and120 Cell Metabolism 11, 113–124, February 3, 2010 ª2010 Elsevier Inc.Y365, reducing the rate of nuclear import
that now results in a greater steady-state
level of LKB1 in the cytoplasm. One
appealing model that can account for
these observations is that Fyn-depen-
dent LKB1 tyrosine phosphorylation
prevents the assembly of LKB1 into the
LKB1/STRADa/MO25 ternary complex,
thereby increasing LKB1 nuclear localiza-
tion. Tyrosine dephosphorylation would
then allow for the formation of the ternary
complex and promote cytosolic LKB1
localization and kinase activation.
In summary, we have demonstrated
that LKB1 is a direct substrate for Fyn
tyrosine kinase, that LKB1 subcellulardistribution is regulated by tyrosine phosphorylation on Y261
and Y365, and that Fyn-dependent redistribution of LKB1 into
the cytoplasm results in increased phosphorylation/activation
of AMPK. Importantly, the positive metabolic effects observed
in Fyn null mice (decreased adiposity and increased energy
expenditure) are reproduced by the acute pharmacological inhi-
bition of Fyn activity, resulting in weight loss via decreased
adiposity without affecting lean mass. Since the deregulation
of the whole-body energy homeostasis is one of the main events
leading to the development of obesity, insulin resistance, and
diabetes, these data highlight the therapeutic potential of inhib-
iting Fyn kinase signaling.
EXPERIMENTAL PROCEDURES
Animals
Eight- to ten-week-old male C57BL6/J, pp59fyn null mice and their controls
were obtained from The Jackson Laboratory (Bar Harbor, ME) and housed in
a facility equipped with a 12 hr light/dark cycle. Animals were fed ad libitum
a standard chow diet (Research Diets, New Brunswick, NJ) containing
75.9% (Kcal) carbohydrates, 14.7% protein, and 9.4% fat. All studies were
Figure 7. Subcellular Localization of LKB1 in Skeletal Muscle In Vivo
Is Regulated by Tyrosine Phosphorylation
(A) Tibialis anterior was transfected with pcDNA-Flag-LKB1-WT (Aa–Ac), the
pcDNA-Flag-LKB1-Y261/365F double mutant (Ad–Af), or the pcDNA empty
vector (Ag–Ai) cDNAs. Immunofluorescence was performed on 10 mm frozen
sections for the localization of LKB1 (Flag antibody) and nuclei (DAPI).
(B) Magnified images of muscles transfected with pcDNA-Flag- LKB1-WT
(Ba–Bc) or the pcDNA-Flag-LKB1-Y261/365F double mutant (Bd–Bf) is shown
to more easily visualize the change in LKB1 localization (see also Figure S7).
Cell Metabolism
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University Institutional Animal Care and Use Committee (IACUC).
Whole-Body Indirect Calorimetry
Oxygen and carbon dioxide consumption were simultaneously determined
by Oxymax open-circuit indirect calorimetry system (eight-cage system)
(Columbus Instruments). Animals were allowed to acclimatize for two com-
plete light and dark cycles (48 hr), and SU6656 injections were performed at
the beginning of the light cycle the following day. Measurements were subse-
quently taken 12 hr following the injection. Data were analyzed as the average
of 1 hr measurements for each mouse. Instrument settings were as follows:
gas flow rate, 0.6 l/min; sample flow rate, 0.5 l/ min; settle time, 120 s; measure
time, 60 s.
Total Body Mass and Magnetic Resonance Imaging
Total body mass (g) was recorded before (T = 0) and 12 hr (T = 12 hr) after the
SU6656 injection. To determine fat and lean mass, animals were placed in
a clear plastic holder without anesthesia or sedation and inserted into the
EchoMRI-3-in-1 System from Echo Medical Systems (Houston, TX, USA).Cell MTotal body fat and lean mass were measured before (T = 0) and after (T =
12 hr) after the injection.
Western Blot Analysis
Animals were injected with vehicle or SU6656 (4 mg/kg) at the beginning of the
light cycle. They were anesthetized and sacrificed by cervical dislocation 3 hr
after the injection. Tissues were rapidly freeze clamped in liquid nitrogen and
stored at 80C. Protein preparation and blotting were performed as
described below. Tissues were ground in liquid nitrogen and homogenized
in a buffer containing 50 mM Tris (pH 7.4), 1% glycerol, and 1% Triton X-100
supplemented with protease inhibitor (Complete Mini, Roche Pharmaceuti-
cals, Nutley, NJ). Homogenates were centrifuged for 30 min at 14,000 rpm
at 4C, and supernatants were collected. Protein concentration was deter-
mined with the BCA Protein Assay (Thermo Scientific, Rockford, IL).
Protein samples (40 mg) were separated on 8% or 10% reducing polyacryl-
amide gels and transferred onto Immobilon-P polyvinylidene difluoride
membranes. Immunoblots were blocked with 2% milk and 3% BSA in Tris-
buffered saline for 60 min at room temperature and incubated overnight at
4C with the indicated antibodies (Cell Signaling, Upstate, and Alpha Diag-
nostic International) in Tris-buffered saline and 0.05% Tween 20 (TBST) con-
taining 1% BSA. Blots were washed in TBST and incubated with horseradish
peroxidase-conjugated secondary antibodies (1:30,000) for 30 min at room
temperature. Membranes were washed in TBST, and antigen-antibody
complexes were visualized by chemiluminescence using an ECL kit (Pierce).
Alternatively, immunoblots were incubated with IRDye800CW goat anti-
mouse (H+L) or IRDye680 goat anti-rabbit (H+L) secondary antibodies, and
signal was detected with the Odyssey Infrared Imaging System (Li-COR
Biotechnology, Lincoln, NE).
Fatty Acid Oxidation in Isolated Muscles
Animals received a single intraperitoneal injection of SU6656 or vehicle in the
morning. Mice were sacrificed by cervical dislocation 3 hr after the injection.
Skeletal muscles (red soleus and white gastrocnemius) were rapidly removed
and preincubated for 10 min in oxygenated (95%O2, 5% CO2) Earle’s solution
(Invitrogen, Carlsbad, CA) supplemented with 5mMD-glucose, 250 mMpalmi-
tate, and 0.5% BSA plus either 10 mM SU6656 or an equal volume of DMSO.
Tissues were incubated for 45 min in the same buffer containing 250 mM
palmitate containing 1 mCi/ml [1-14C] palmitate tracer (Amersham, Piscat-
away, NJ) bound to 0.5% BSA. Incubations were carried out under an atmo-
sphere of 95%O2/5%CO2 at 30
C in glass vials (Kontes, Vineland, NJ) equip-
ped with a center well filled with 200 ml of 2N NaOH (trapping agent). At the
end of the incubation, perchloric acid was added through the cap to a
concentration of 0.6 mM, and vials were incubated for 3 hr at 30C with
moderate shaking. The 14CO2 produced was determined by scintillation
counting of NaOH using the UniScintBD scintillation liquid (National Diagnos-
tics, Atlanta, GA).
Cell Culture
C2C12 myoblasts were grown in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen, Carlsbad, CA) with 10% fetal bovine serum. Differentiation
into myotubes was initiated by switching the myoblasts to DMEM comple-
mented with 2% horse serum for 4–6 days as described previously (Yaffe
and Saxel, 1977a, 1977b). 3T3L1 preadipocytes were cultured in DMEM sup-
plemented with 10% calf serum at 37C. Confluent cultures were induced to
differentiate into adipocytes as described previously (Min et al., 1999).
cDNA Constructs
pcDNA3.1-Fyn-V5 was generated by RT-PCR performed on spleen total RNA
using the SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad,
CA) with a pair of oligonucleotides: 50-CACCATGGGCTGTGTGCAATGT
AAGG-30 and 50-CAGGTTTTCACCGGGCTGAT-30. The PCR product was
separated on 2% agarose gel, and the specific single band was extracted
using the QIAquick PCR purification kit (QIAGEN). The purified PCR product
was cloned into the pcDNA3.1D/V5-His-TOPOusing the pcDNA3.1 Directional
TOPO Expression Kit (Invitrogen,Carlsbad, CA). pcDNA3.1-Fyn-CA(Y527F)-
V5 was obtained using the oligonucleotides 50-CACCATGGGCTGTGTGCAA
TGTAAGG-30 and 50-CAGGTTTTCACCGGGCTGAAACTGGGGCTCT-30 and
following the same protocol. pcDNA3.1-Fyn-KD(K299M)-V5 was constructedetabolism 11, 113–124, February 3, 2010 ª2010 Elsevier Inc. 121
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the pair of oligonucleotides 50-CACCATGGGCTGTGTGCAATGTAAGG-30
and 50-CTGGCTTAAGGGTCATTATGGCTACTTTT-30 and the pair of oligonu-
cleotides 50-AAAAGTAGCCATAATGACCCTTAAGCCAG-30 and 50-CAGGTT
TTCACCGGGCTGAT-30. PCR products were extracted and purified. Each
product was mixed, and a second PCR was performed using the oligonucle-
otides 50-CACCATGGGCTGTGTGCAATGTAAGG-30 and 50-CAGGTTTTCAC
CGGGCTGAT-30. Products were cloned into the pcDNA3.1D/V5-His-TOPO.
The pYX-LKB1 construct was obtained from Open biosystems (Rockford, IL)
and used to generate the pcDNA3.1-Flag-LKB1 construct. The gene encoding
LKB1 was amplified with the oligonucleotides 50-ATGGACTACAAGGACGAT
GACGACAAGATGGACGTGGCGGACCCC-30 and 50-TCACTGCTGCTTGCA
GGC-30 and cloned to pcDNA3.1D/V5-His-TOPO. pEGFPC2 and pcDNA3.1-
LKB1 were digested by Hind3 and Sac2. Products were purified and ligation
was performed using the DNA Ligation Kit (Takara, Shiga, Japan) to obtain
the pEGFPC2-LKB1 construct. LKB1mutants were obtained using an overlap-





AC-30, 50-GTTCTCAAAGAGCTTGAAGATATTGTCCCC-30; and LKB1-Y365F,
50-GACGGCATTATCTTCACCCAGGACTT-30, 50-AAGTCCTGGGTGAAGATA
ATGCCGTC-30. LKB1-Y261/365F was obtained using primers for LKB1-
Y261F and for LKB1-Y261F. The GST-AMPK a subunit and Omni-STRADa
cDNAs were kind gifts from Dr. Bin Zheng, Harvard Medical School.In Vitro LKB1 Phosphorylation Assay
His-LKB1 fusion protein was purified using HisPur Purification kit and Slide-A-
Lyzer Dialysis Cassette (Pierce,Rockford, IL). His-LKB1 protein (1 mg) was
incubated with the recombinant His-FynT kinase (1.8U) (Calbiochem, Gibbs-
town, NJ) in presence of Src Mg/ATP cocktail (Millipore, Billerica, MA), and
kinase reaction was performed for 1 hr at 35C. Samples were separated on
10% SDS-polyacrylamide gels, and immunoblotting was performed with
PY100 monoclonal antibody and LKB1 polyclonal antibody. Signals were de-
tected with the Odyssey Infrared Imaging System (Li-COR Biotechnology,
Lincoln, NE).Transfection of C2C12 Myotubes and 3T3L1 Adipocytes
C2C12 myotubes and 3T3L1 adipocytes were electroporated as previously
described (Waters et al., 1995). A suspension of 3T3L1 adipocytes was elec-
troporated with 500 mg of plasmid under low-voltage condition (0.16 kV, 950
mF). C2C12 myotubes were electroporated with a total of 250 mg of plasmid
under 0.22 kV, 950 mF. Adipocytes and myotubes were allowed to adhere
onto collagen-coated tissue culture dishes for 30–48 hr.Transfection of Skeletal Muscle In Vivo
Three-month-old wild-type mice were anesthetized with isoflurane, and the
right tibialis anterior was injected with 125 mg of pcDNA3-Flag-LKB1-WT or
pcDNA3-FlagLKB1-(Y261/365F) cDNAs and the left tibialis anterior with the
pcDNA empty vector as control. Electroporation (eight shocks) was performed
using the S48 Square Pulse Stimulator (Grass Technologies, West Warwick,
RI) with the following settings: train rate, 1 TPS; train duration, 500 ms; pulse
rate, 1 PPS; duration, 20 ms; voltage, 80V. Electroporation was repeated
5 days later. Animals were sacrificed 5 days after the second set of electropo-
ration. The tibialis anterior muscles were rapidly removed and immediately
embedded into optimal cutting temperature (O.C.T.) compound (Sakura Fine-
tek USA, Inc., Torrance, CA). Tissues were frozen in liquid nitrogen. Frozen
sections (10 mm) were prepared and subjected to immunofluorescence
labeling as previously described, using anti-Flag mouse mAb antibody and
Alexa Fluor 488 anti-mouse secondary antibody. Sections were washed three
times with PBS and mounted with Prolong Gold antifade reagent with DAPI
(Invitrogen, Carlsbad, CA) and were imaged as described above. Settings
(Iris [pinhole], laser intensity, gain, and offset) were fixed and identical for all
samples. Muscle extracts were also used for immunoprecipitation and immu-
noblotting as described below.122 Cell Metabolism 11, 113–124, February 3, 2010 ª2010 Elsevier InSignal Quantification
The ratio of cytosolic and nuclear LKB1 was quantified using the Image J soft-
ware (National Institutes of Health). Images of 15 representative cells were pro-
cessed, and results represent mean ± SE from three independent experi-
ments.
Immunoprecipitation
Cells were homogenized in a NP-40 lysis buffer containing 25 mM HEPES
(pH 7.4), 10% glycerol, 50 mM sodium fluoride, 10 mM sodium phosphate,
137mM sodium chloride, 1 mM sodium orthovanadate, 1 mMPMSF, 10 mg/ml
aprotinin, 1 mg/ml pepstatin, and 5 mg/ml leupeptin and rocked for 10 min at
4C. Muscle extracts (100 mg) were homogenized in the Bullet Blender
(Next Advance, Inc., Averill Park, NY) using zirconium silicate beads (speed
8 for 3 min) in the buffer described above. Homogenates were centrifuged
for 10–30 min at 13,000 g at 4C, and supernatants were collected. Protein
concentration was determined using the BCA protein assay. Cell lysates
(3–4 mg) were incubated with 10 mg of antibody for 2 hr at 4C. TrueBlot
anti-rabbit Ig IP Beads (50 ml) (eBioscience, Inc., San Diego, CA) were added,
and samples were rocked for 60min at 4C. Samples were washed three times
with NP-40 lysis buffer and were resuspended in 100 ml of Laemmli buffer con-
taining 50 mM DTT. Samples were heated at 90–100C for 10 min and centri-
fuged at 10,000 3 g for 3 min. Supernatants were collected and loaded on
10% SDS-polyacrylamide gels.
Immunofluorescence
C2C12 myotubes were cotransfected with 50 mg pEGFP-C2-LKB1 or
pcDNA3-Flag-LKB1 or pcDNA3-Flag-LKB1 mutants and 200 mg of the indi-
cated pcDNA3-Fyn constructs. Transfected cells were washed with PBS
and fixed for 10 min in PBS containing 4% PFA and 0.2% Triton X-100. Immu-
nofluorescence was performed using a rabbit LKB1 polyclonal antibody,
a rabbit Flag-specific polyclonal antibody, and a mouse Fyn monoclonal anti-
body followed by Alexa Fluor 488 anti-rabbit IgG and Alexa Fluor 594 anti-
mouse IgG. Samples were mounted on glass slides with Prolong Gold antifade
reagent with DAPI (Invitrogen, Carlsbad, CA). Cells were imaged using
a confocal fluorescencemicroscope (TCS SP5 confocal; LeicaMicrosystems).
Statistics
Results are expressed as mean ± standard error of the mean (SEM). Differ-
ences between animals and/or treatments were tested for statistical signifi-
cance (p < 0.05) using Student’s unpaired t test.
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